Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | TOP2A | P11388 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.47 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 5/20 | 0.46 |
| ▸ | AGTR1 | P30556 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17963025 | 1.00 | KDM4E (0.68) | KDM4EALDH1A1TOP2ARAB9ASMN1; SMN2 | |
| SCHEMBL25162057 | 1.00 | KDM4E (0.68) | KDM4EALDH1A1TOP2ARAB9ASMN1; SMN2 | |
| SCHEMBL31494657 | 1.00 | KDM4E (0.68) | KDM4EALDH1A1TOP2ARAB9ASMN1; SMN2 | |
| SCHEMBL1256130 | 0.83 | KDM4E (0.73) | KDM4EALDH1A1TOP2ARAB9ASMN1; SMN2 | |
| SCHEMBL241401 | 0.81 | KDM4E (0.70) | KDM4EALDH1A1TOP2ARAB9ASMN1; SMN2 | |
| SCHEMBL167986 | 0.81 | KDM4E (0.70) | KDM4EALDH1A1TOP2ARAB9ASMN1; SMN2 | |
| SCHEMBL1384556 | 0.81 | KDM4E (1.00) | KDM4EALDH1A1TOP2ARAB9ASMN1; SMN2 | |
| SCHEMBL19386605 | 0.81 | KDM4E (0.70) | KDM4EALDH1A1TOP2ARAB9ASMN1; SMN2 | |
| SCHEMBL3660657 | 0.81 | KDM4E (1.00) | KDM4EALDH1A1TOP2ARAB9ASMN1; SMN2 | |
| SCHEMBL20412512 | 0.81 | KDM4E (0.53) | KDM4EALDH1A1TOP2ARAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1224005-A | Anticancer thiosemicarbazides compounds and their producing process | MINGSHENG KAIPU PHARMACEUTICAL (CN) | 1999-07-28 | — | — | CN | claimed |
| US-5011932-A | Anthelmintic pyridinyl acylhydrazones derivatives | UPJOHN COMPANY (US) | 1991-04-30 | — | — | US | claimed |
| EP-0214158-A1 | ANTHELMINTIC PYRIDINYL ACYLHYDRAZONES, METHOD OF USE AND COMPOSITIONS | THE UPJOHN COMPANY (US) | 1987-03-18 | — | — | EP | claimed |
| WO-1986004582-A1 | ANTHELMINTIC PYRIDINYL ACYLHYDRAZONES, METHOD OF USE AND COMPOSITIONS | THE UPJOHN COMPANY (US) | 1986-08-14 | — | — | WO | claimed |
| WO-2020107221-A1 | CHEMICAL ACTIVATORS OF NICOTINAMIDE MONONUCLEOTIDE ADENLYLY TRANSFERASE 2 (NMNAT2) AND USES THEREOF | TSINGHUA UNIVERSITY (CN) | 2020-06-04 | — | — | WO | disclosed |
| US-20200062839-A1 | USE OF DIANHYDROGALACTITOL OR ANALOGS AND DERIVATIVES IN COMBINATION WITH VEGF INHIBITORS TO TREAT CANCER | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2020-02-27 | — | — | US | disclosed |
| WO-2016123246-A1 | (THIO, OXO AND SELENO) SEMICARBAZONE COMPLEXES WITH ZINC AND THEIR USE FOR TREATING CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-08-04 | — | — | WO | disclosed |
| US-20150302140-A1 | IN SILICO IDENTIFICATION OF CANCER MOLECULAR SIGNALING PATHWAYS AND DRUG CANDIDATES | H. LEE MOFFIT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2015-10-22 | — | — | US | disclosed |
| CN-101784543-B | Indole and indazole compounds as inhibitors of cellular necrosis | LG LIFE SCIENCES LTD | 2013-10-16 | — | — | CN | disclosed |
| CN-101784543-A | Indole and indazole compounds as inhibitors of cellular necrosis | LG LIFE SCIENCES LTD | 2010-07-21 | — | — | CN | disclosed |
| CN-1224005-A | Anticancer thiosemicarbazides compounds and their producing process | MINGSHENG KAIPU PHARMACEUTICAL (CN) | 1999-07-28 | — | — | CN | disclosed |
| US-5023334-A | Anthelmintic pyridinyl acylhydrazones | THE UPJOHN COMPANY (US) | 1991-06-11 | — | — | US | disclosed |
| US-5011932-A | Anthelmintic pyridinyl acylhydrazones derivatives | UPJOHN COMPANY (US) | 1991-04-30 | — | — | US | disclosed |
| EP-0214158-A1 | ANTHELMINTIC PYRIDINYL ACYLHYDRAZONES, METHOD OF USE AND COMPOSITIONS | THE UPJOHN COMPANY (US) | 1987-03-18 | — | — | EP | disclosed |
| WO-1986004582-A1 | ANTHELMINTIC PYRIDINYL ACYLHYDRAZONES, METHOD OF USE AND COMPOSITIONS | THE UPJOHN COMPANY (US) | 1986-08-14 | — | — | WO | disclosed |
| EP-0153340-A1 | A BIOCIDAL, PARTICULARLY FUNGICIDAL AND/OR BACTERICIDAL COMPOSITION AND THIOSEMICARBAZONES AND METAL COMPLEXES THEREOF FOR USE IN THE COMPOSITION | A/S CHEMINOVA (DK) | 1985-09-04 | — | — | EP | disclosed |
| WO-1985000955-A1 | A BIOCIDAL, PARTICULARLY FUNGICIDAL AND/OR BACTERICIDAL COMPOSITION AND THIOSEMICARBAZONES AND METAL COMPLEXES THEREOF FOR USE IN THE COMPOSITION | A/S CHEMINOVA (DK) | 1985-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062839-A1 | USE OF DIANHYDROGALACTITOL OR ANALOGS AND DERIVATIVES IN COMBINATION WITH VEGF INHIBITORS TO TREAT CANCER | PGF, HDGF, VEGFA | KDM4E 3345/4885ALDH1A1 1359/4885TOP2A 1431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.